This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Zheng, R. Articles by Koski, G. K. PubMed PubMed Citation Articles by Zheng, R. Articles by Koski, G. K.

Paired Toll-like Receptor Agonists Enhance Vaccine Therapy through Induction of Interleukin-12

Center for Surgery Research, Department of Immunology, Cleveland Clinic, Cleveland, Ohio

Requests for reprints: Gary K. Koski, Center for Surgery Research, Department of Immunology, Lerner Research Institute, Cleveland Clinic, NE6, 9500 Euclid Avenue, Cleveland, OH 44195. Phone: 216-445-3804; Fax: 216-445-3805; E-mail: dendritic_cell{at}hotmail.com.

Key Words: tumor immunity • vaccination • dendritic cells • rodent • cytokines

Minimal requirements for generating effective immunity include the delivery of antigenic (signal 1) and costimulatory (signal 2) signals to T lymphocytes. Recently, a class of third signals, often delivered by antigen-presenting dendritic cells, has been shown to greatly enhance immune responses, especially against tumors. Among signal 3 factors, interleukin (IL)-12 is particularly effective and can be conditionally induced by agonists of Toll-like transmembrane receptors (TLR). In this study, we assessed the therapeutic effect of adjuvant TLR agonist administration upon the capacity of dendritic cell (DC)-tumor electrofusion hybrids to eradicate established MCA205 sarcomas in syngeneic mice. Paired, but not solitary combinations of polyinosine:polycytadilic acid (P[I:C]; TLR3 agonist) and CpG DNA (ODN1826l; TLR9 agonist) stimulated IL-12 secretion from DCs in vitro and synergized with vaccination to achieve potent tumor rejection. Therapeutic effects, however, required coadministration of paired TLR agonists and DC-tumor fusion hybrids. The administration of TLR agonists alone or with fusion vaccine induced transient splenomegaly but without apparent toxicity. The therapeutic effects of this immunization regimen were significantly abrogated through the neutralization of IL-12p70, indicating that production of this third signal was essential to the observed tumor regression. These results show the profound functional consequences of TLR cooperativity and further highlight the critical role of IL-12 in antitumor immunity. [Cancer Res 2008;68(11):4045–9]